Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, has announced its preliminary results for the year ended 30 June 2020. Financial Highlights · 7% revenue..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field...
Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short-course subcutaneous allergy immunotherapy (SCIT) platform, which continues to..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provided a trading update for the year ended 30 June 2020 ahead of its Preliminary..
Allergy Therapeutics PLC (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announced its unaudited interim results for the six months ended 31 December 2019. Highlights Financial..
Allergy Therapeutics (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced publication of positive preclinical results of its peanut allergy vaccine candidate in The Journal of..
Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues to..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has provided a trading update for the six months ended 31 December 2020 ahead of..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today provided an update on its Grass MATA MPL phase III study, due to..
Allergy Therapeutics plc (LON: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced its preliminary results for the year ended 30th June 2019. Highlights Financial Highlights..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today provided a trading update for the year ended 30 June 2019 ahead of..
Allergy Therapeutics plc (LON: AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to..
Commenting on announcement, Manuel Llobet, CEO of Allergy Therapeutics, said: “Allergy Therapeutics has continued to perform strongly this year, combining good sales performance with strong cost control, resulting in earnings..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announced today that it has received a $7.6m settlement from Inflamax Research Inc. in relation..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announced today that Mary Tavener will join the Board of Allergy Therapeutics as a Non-Executive..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced positive Phase I safety and tolerability results of subcutaneous Acarovac MPL (Monophosphoryl..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced, through its adjuvant research division Bencard Adjuvant Systems, the publication of new..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the outcome of successful discussions with the Paul Ehrlich Institut in Germany..
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced top-line results from the Phase III clinical trial B301of its new adjuvanted..
